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AFTER THE FIRE AND RAIN, LILLY STILL
STANDS.
Enzo Biochem, Inc. v. Gen-Probe, Inc., 296 F.3d 1316
(Fed. Cir. 20 02).
Carrie A. Morgan∗

I.

INTRODUCTION

As biotechnological1 inventions have progressed, inventors have
increasingly sought patent protection to try to recoup some of the costs of
their research. Along with the increase in the number of biotech patents
issued, the number of infringement cases, and the assertion of patent
invalidity as a defense to infringement have increased.2 With more and
more frequency, accused infringers are challenging biotechnological patents
on the issue of sufficiency of the written description requirement.3 This is
precisely what happened in Enzo Biochem, Inc. v. Gen-Probe, Inc.4
In Enzo, the Federal Circuit confronted the issue of whether
biological material deposited in a public access bank5 and referenced in a
patent application with regards to a described function could fulfill the
written description requirement in 35 U.S.C. § 112.6 The Federal Circuit
previously required biological inventors to disclose the sequence of the
DNA material in the specification.7 In Enzo, however, the court held the
deposit of the DNA material in the biological material bank combined with
the functional description and reference to the sample in the description of

* Associate, Dinsmore & Shohl LLP; J.D. University of Dayton School of Law, summa cum laude,
2005; B.S. Cell and Developmental Biology, University of Rochester, 1999.
1
Biotechnological can also be referred to as biotech.
2
Patent infringement is governed by 35 U.S.C. § 271, which provides, “[e]xcept as otherwise provided in
this title, whoever without authority makes, uses, offers to sell, or sells any patented invention, within the
United States or imports into the United States any patented invention during the term of the patent
therefor, infringes the patent.” 35 U.S.C.A. § 271(a) (West 2000).
3
The writ ten description requirement is set forth at 35 U.S.C. § 112 ¶ 1. It reads, “[t]he s pecification
shall contain a written description of the invention.” 35 U.S.C.A. § 112 (West 2000).
4
296 F.3d 1316 (Fed. Cir. 2002).
5
Inventors originally deposited biological material in a publicly accessible bank to help fulfill the
enablement requirement. Enzo, 296 F.3d at 1325. Enablement is another statutory requirement in 35
U.S.C. § 112, which requires the inventor to disclose in the specification enough information to enable
the public to make and use the invention. Id.
6
See supra n. 3 and accompanying text.
7
Enzo, 296 F.3d at 1325.
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the invention was sufficient to meet the written description requirement.8
The decision handed down by the Federal Circuit in Enzo was a
misleading decision, which commentators have incorrectly read as relaxing
the very strict written description requirement.9 In actuality, the court
correctly worded the opinion as a factual exception to the rule solidified in
Regents of the University of California v. Eli Lilly & Co ., which required a
biological invention consisting of DNA to disclose the exact sequence of the
DNA to meet the written description requirement.10 By doing so, the
Federal Circuit has shown that it has some flexibility in regards to
fulfillment of the written description requirement but generally, the rule set
out in Lilly will stand. A biotech patent challenged on written description
sufficiency will still have to disclose the sequence of the claimed DNA in
order to be valid.
This note will argue that the court deliberately worded the opinion
as a fact based exception to Lilly, which resulted in a return to the
requirement of disclosure of the DNA sequence for inventions claiming
DNA. Section II will provide a brief history of the written description
requirement and Lilly. Section II will also establish the background of Enzo,
its procedural history, and the court’s rationale. Section III will argue that
the historical importance of the written description requirement; historical
treatment of precedent in this area; the actual language of the opinion; and
the changes in technology will cause the court to restrict the holding in Enzo
to its facts. Finally, Section IV will conclude.
II.

BACKGROUND

A thorough understanding of the written description requirement
necessitates an examination of several precedents. First, federal statutes and
their amendments began to form the outline for the written description
requirement in a patent application. Second, the Court of Customs and
Patent Appeals revived the written description requirement for priority
issues in In re Ruschig,11 and the Supreme Court's decision in Lilly further
expanded the written description requirement as an avenue for patent
invalidity. Finally, Enzo represents the Federal Circuit's attempt to reconcile
the written description requirement of the patent application with current
gene mapping technology.
A.

The Historical Development of the Written Description Requirement
In order to qualify for patent protection, the patent application must

8

Id. (holding “that reference in the specification to a deposit in a public depository, which makes its
contents accessible to the public when it is not otherwise available in written form, constitutes an
adequate description of the deposited material sufficient to comply with the written description
requirement”).
9
The Fede ral Circuit held that a deposit of biological material could help satisfy the written description
requirement. Id. at 1330.
10
119 F.3d 1559, 1567 (Fed. Cir. 1997) (holding that a written description for DNA was invalid unless it
disclosed the sequence of the DNA being claimed).
11
379 F.2d 990 (Cust. & Pat. App. 1967).
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meet five separate requirements: (1) patentable subject matter;12 (2) utility;13
(3) novelty;14 (4) nonobviousness;15 and (5) specification.16
The
specification requirement includes three sub-requirements: (1) enablement;17
(2) written description;18 and (3) best mode.19 This note will focus on the
written description requirement codified at 35 U.S.C. § 112.20
Since its inception in the Patent Act of 1793, the wording of the
written description requirement has essentially stayed the same although its
function has greatly changed.21 When originally introduced, the written
description requirement’s function was to define the limits of the
invention.22 When the Patent Act of 1870 introduced claims23 into the
specification24 with the purpose of having them define the limits of the
claimed invention, the exact function of the written description requirement
became uncertain.25 Even though the new act still maintained the written
description language, it was unclear at that time what function the written
description requirement would serve.26
In 1967, the Court of Customs and Patent Appeals27 decided In re
Ruschig and gave the written description requirement its first real function
since the statutory amendments.29 In that case, the issue was whether the
original specification described the amended claim, so that it could have the
benefit of the original filing date. 30 The court found the enablement
28

12

35 U.S.C.A. § 101 (West 2000) (stating “[w]hoever invents or discovers any new and useful process,
machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain
a patent therefor, subject to the conditions and requirements of this title”).
13
Id.
14
35 U.S.C.A. § 102 (West 2000 & Supp. 2005).
15
35 U.S.C.A. § 103 (West 2000 & Supp. 2005).
16
35 U.S.C.A. § 112.
17
See supra n. 5 and accompanying text.
18
See supra n. 3 and accompanying text.
19
The best mode requirement states that the specification “set forth the best mode contemplated by the
inventor of carrying out his invention.” 35 U.S.C.A. § 112 ¶ 1.
20
See supra n. 3 and accompanying text.
21
See Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1561-64 (Fed. Cir. 1991) (stating the Patent Act of
1793 required the applicant to “deliver a written description of his invention”). The modern Act requires
“[t]he specification shall contain a written description of the invention.” 35 U.S.C.A. § 112 ¶ 1.
22
Vas-Cath, 935 F.2d at 1561.
23
See United Carbon Co. v. Binney & Smith Co., 317 U.S. 228, 232 (1942) (stating that claims set the
boundaries for the patent rights of the claimed invention).
24
The specification is the part of the patent document, which incorporates the description of the
invention and the claims. Roger E. Schechter & John R. Thomas, Intellectual Property: The Law of
Copyrights, Patents and Trademarks 394 (West 2003). When looking to the written description
requirement, the courts usually refer to the specification as the pertinent document but limit the inquiry to
the description and not the claims. Id. at 397.
25
Vas-Cath, 935 F.2d at 1563.
26
Id.
27
This was the predecessor court to the United States Court of Appeals for the Federal Circuit. Martin J.
Adelman, Randall R. R ader, John R. Thomas & Harold C. Wegner, Cases and Material on Patent Law
16 (2d e d., West 2003).
28
In re Ruschig, 379 F.2d 990.
29
See supra nn. 21-26 and accompanying text.
30
35 U.S.C.A. § 119 (West 2000 & Supp. 2005) (allows an inventor to add claims to a patent application
already in process as long as the new claims fall within the scope of the invention as described in the
original application).
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requirement31 was satisfied, but the original specification did not adequately
describe the newly claimed invention.32 The court held that in order for the
amended claim to receive the benefit of the original filing date, the scope of
the amended claim had to be within the written description of the original
application. 33 Because the original specification failed to describe the
compound by its structure and could have been one of several different
compounds,34 the court found the initial disclosure was inadequate as to the
amended claim.35 The court wanted to be sure that the inventor was in
possession of the amended claim at the time of the original filing. 36
Otherwise, the inventor would get the advantage of the earlier filing date for
something he had not even invented at that time. Although the court stated
it was not sure whether priority of an invention was an issue under § 112,37
the decisions that followed firmly grounded inventive priority decisions38 on
the written description requirement in §112.39
B.

The Further Revival of the Written Description Requirement in
Biotech Inventions through Lilly

Even though the Court of Customs and Patent Appeals in In re
Ruschig revived the written description requirement specifically for priority
issues,40 the Federal Circuit did not limit its use to that function.41 The
Federal Circuit expanded the use of the written description requirement
beyond the priority context by establishing it as another avenue upon which
courts could find patents or their claims to be invalid.42 The Federal Circuit
especially placed emphasis on the written description requirement in this
new context in the chemical and biotechnology sectors after the court
realized, through In re Ruschig, that specifications for biological and
chemical inventions could enable without adequately disclosing the
invention43 to one skilled in the art,44 giving inventors the ability to claim

31

See supra n. 5 and accompanying text.
In re Ruschig, 379 F.2d at 996.
33
Id. at 995.
34
Id. at 992 (stating “The compound . . . is not named or identified by formula and it can find support
only as choices made between the several variables involved. This is not regarded as adequate s upport
for a specific compound never named or otherwise exemplified in the specification as filed.”).
35
Id.
36
Id. at 996 (asking whether the specification conveys the information that the applicant actually
invented the compound).
37
Id. at 995 (stating that the original disclosure would enable someone skilled in the art to make the
newly claimed invention, but the original disclosure failed to describe the compound, which would make
this a written description question if it was actually an issue under § 112).
38
Cases disputing whether amended claims can relate back to the original filing date under 35 U.S.C. §
119 are generally called priority disputes.
39
See e.g. Vas-Cath, 935 F.2d at 1555 (holding that summary judgment was inappropriate because
drawings could be used to satisfy the written description requirement to allow a subsequent claim to
receive the benefit of the date of the earlier application).
40
Id.
41
See e.g. Lilly, 119 F.3d 1559 (Fed. Cir. 1997) (holding that the original specification failed to meet the
written description requirement for one of the original claims and that claim was therefore invalid).
42
Id.
43
In Re Ruschig, 379 F.2d at 990; see also Lilly, 119 F.3d at 1567 (stating that the original specification
may have provided an adequate disclosure, but “it does not provide a written description of the cDNA
32
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and monopolize something they never really invented. The Federal
Circuit’s concern for over breadth of claims led to a very stringent written
description requirement, which the court handed down in University of
California v. Eli Lilly.45
In Lilly, the University of California’s research led to the isolation
and cloning of rat cDNA46 for insulin.47 Further testing revealed the use of
non-human insulin had some success in humans.48 In addition, it was well
known in the industry that insulin proteins were very similar among very
diverse species.49 With the above knowledge, in 1977 the University
applied for a patent for the recombinant DNA technology for insulin.50 The
initial claim for the patent was a very broad claim encompassing all
prokaryotic organisms and then the claims subsequently narrowed to
mammalian organisms and then to humans.51 Although the insulin gene in
humans had not been isolated at the time, the University described the
amino acid sequence for the human insulin protein52 and a method for
obtaining and cloning the insulin gene sequence.53 Eventually, Lilly
separately obtained the technology for isolating the human insulin gene,
isolated it, copied it, and used it to treat patients with diabetes.54 The
University of California then filed suit against Lilly for infringement of its
patent. 55
When the court looked at the patent in question, it found that there
was no adequate written description of the claims Lilly was allegedly
infringing.56 Specifically, the court held that an adequate description of the
human insulin gene required “a precise definition, such as by structure,
formula, chemical name, or physical properties.”57 Since the University had
encoding human insulin, which is necessary to provide a written description in the subject matter of [the]
claim”).
44
The court looks at inquiries into patent validity through the eyes of one skilled in the art. 35 U.S.C. §
112. To determine the level of ordinary skill in the art, the court will look to the following factors: “(1)
the education level of the inventor; (2) type of problems encountered in the art; (3) prior art solutions to
those problems; (4) rapidity with which inventions are made; (5) sophistication of the technology; and (6)
education level of active workers in the field.” Envtl. Designs, Ltd. v. Union Oil Co., 713 F.2d 693, 696
(Fed. Cir. 1983).
45
Lilly, 119 F.3d at 1559.
46
cDNA is complimentary DNA which is a strong cloned copy of weaker messenger RNA which is used
to encode proteins. Velander v. Garner, 348 F.3d 1359 (Fed Cir. 2003). The cDNA is then placed into a
bacterial host which will then manufacture the desired protein (in Lilly, the scientists were producing
insulin). In re O’Farrell, 853 F.2d 894, 898 (Fed. Cir. 1988).
47
Lilly, 119 F.3d at 1562. The significance of human versus mammalian insulin was that some people
had exhibited severe reactions to the non-human insulin. Id. Human insulin was much less likely to
cause these reactions, so there was a ready market for whoever isolated the human insulin gene. Id.
48
Id.
49
Id.
50
Id. at 15 59.
51
Id. at 15 63.
52
Even though the University had isolated the human insulin protein, redundancy in the genetic code
prevented them from disclosing the exact sequence of the gene that encoded for human insulin without
isolating the gene itself. Id.
53
Id.
54
Id.
55
Id. at 15 62.
56
Id. at 15 68.
57
Id. at 1566.
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not isolated the gene, they did not have and could not get the DNA sequence
for the gene.58 Because the University described the process for obtaining
the DNA in question and not the sequence of the DNA itself, the court held
the disclosure was not sufficient to meet the written description
requirement.59
C.

Facts of Enzo Biochem, Inc. v. Gen-Probe, Inc.

Enzo Biochem was the assignee60 of a patent for the ability of a
DNA probe to preferentially hybridize with Neisseria Gonorrhoeae over
Neisseria Meningitidis. 61 Since N. gonorrhoeae and N. meningitidis have
about 93% homology,62 doctors were getting back false positive results for
tests for gonorrhea because the test probes were actually detecting N.
meningitidis.63 With this new probe, the accuracy of the test results was
greatly improved.64
The patent in question described the invention as “a composition of
matter specific for [N.] gonorrhoeae . . . which hybridizes to chromosomal
DNA of [N.] gonorrhoeae” over the chromosomal DNA of N. meningitidis
at a ratio greater than about five.65 Additional claims go on to describe the
complimentary strands to which the DNA probe will preferentially bind (the
target sequence), how the inventors discovered the binding rate, and how
that rate was calculated. In the specification, Enzo Biochem made reference
to the fact that it had deposited the specifically claimed nucleotide
sequences in a publicly accessible DNA bank.66
D.

Procedural History of Enzo

Enzo Biochem believed that Gen-Probe was infringing on its patent,
so it brought an action against Gen-Probe for patent infringement.67 GenProbe moved for summary judgment, claiming the patent was invalid for
failure to meet the written description requirement.68 Guided by Lilly, the
United States District Court for the Southern District of New York found
that the written description requirement was lacking because the

58

Id. at 15 63.
Id. at 15 68.
60
An assignee of a patent is a person or entity to whom the inventor has signed over his patent rights. 35
U.S.C.A § 152 (West 2000). This is common in employer/employee relationships.
61
A DNA probe is a small piece of DNA with a known sequence, which is used to target a
complimentary sequence on a large strand of DNA, which the researcher is trying to isolate. Enzo, 296
F.3d at 1321.
62
Homology is the similarity between two strands of DNA. Id. Here the two strands were 93%
homologous, which means that 93% of their sequences were the same. Id. This made it tough for
researchers to find a probe that would target one but not the other and led to a lot of incorrect test results.
Id.
63
Id.
64
Enzo, 296 F.3d at 1320-21.
65
Id. at 13 21.
66
See supra n. 5 and accompanying text.
67
Patent infringement is governed by 35 U.S.C.A. § 271.
68
See supra n. 3 and accompanying text.
59
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specification did not state the structure of the DNA probe.69 The United
States Court of Appeals for the Federal Circuit affirmed the lower court’s
decision also relying on the reasoning of Lilly.70 Enzo Biochem petitioned
for a rehearing to determine the issue of whether a deposit could help fulfill
the written description requirement. The Federal Circuit granted the
rehearing and the same three judges that heard the initial appeal reversed
their earlier decision holding that the facts surrounding and including the
deposit in this case could satisfy the written description requirement.71 The
court denied a motion to rehear the case en banc.72
E.

On Rehearing, the Court’s Rationale in Enzo

Reviewing its own earlier decision, the court seemed to loosen the
restriction of its earlier decision in Lilly by stating that not all functional
descriptions of genetic material will fail to meet the written description
requirement.73 The court looked to the United States Patent and Trademark
Office (“PTO”) guidelines, which had addressed this issue to a certain
extent and used them as guidance.74 According to the PTO guidelines, a
functional description of a nucleic acid probe would be sufficient if the
specification could link that function to a structure which is sufficiently
known or which the specification discloses.75
Next, the court considered whether the deposit would link the
functional description to a structure that is sufficiently known or disclosed.
The court held that:
[R]eference in the specification to a deposit
in a public depository, which makes its
contents accessible to the public when it is
not otherwise available in written form,

69
Enzo Biochem, Inc. v. Gen-Probe, Inc., 2001 U.S. Dist. LEXIS 23791 (S.D.N.Y. Apr. 4, 2001), rev’d
in part on other grounds, 323 F.3d 956 (Fed. Cir. 2002).
70
Enzo Biochem, Inc. v. Gen-Probe, Inc., 285 F.3d 1013 (Fed. Cir. 2002), vacated, 296 F.3d 1316 (Fed.
Cir. 2002). In order to encourage greater efficiency and more uniform decisions in several areas of law,
Congress established the United States Court of Appeals for the Federal Circuit in 1982. This court hears
all appeals from federal district courts on issues relating to certain subjects, patent law is one of them.
The U.S. Court of Appeals for the Federal Circuit: “An Act To establish a United States Court of
Appeals for the Federal Circuit, to establish a United States Claims Court, and for other purposes.”,
http://air.fjc.gov/history/landmark/22a_frm.html (accessed Sept. 9, 2005).
71
Enzo, 296 F.3d at 1320.
72
Enzo Biochem, Inc. v. Gen-Probe, Inc., 42 Fed. Appx. 439 (Fed. Cir. 2002). Within the opinion
denying the en banc petition arose a disagreement amongst the justices of the Federal Circuit. Id. The
majority opinion espoused the view that the written description requirement was grounded in the history
of patent law and was here to stay while the dissent argued that the written description requirement
should be limited to issues of priority and should never have been elevated to the position it holds today
over the validity of patents. Id.
73
Enzo, 296 F.3d at 1324.
74
Id.
75
See 66 Fed. Reg. 1099, 1106 (Jan. 5, 2001) (stating that the specification meets the written description
requirement by showing “that an invention is complete by disclosure of sufficiently detailed, relevant
identifying characteristics . . . i.e., [complete or partial] structure, . . . other physical and/or chemical
properties, . . . functional characteristics [when] coupled with a known or disclosed correlation between
function and structure, or [some] combination of such . . . characteristics”).
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constitutes an adequate description of the
deposited material sufficient to comply
with the written description requirement . . .
.76
Specifically, even though the structures were not stated within the
specification, “those structures may not have been reasonably obtainable
and in any event were not known to Enzo [Biochem] when it filed its
application in 1986.”77 As a result, the court allowed Enzo Biochem to
satisfy the written description requirement based on the disclosure of the
target DNA strands and the deposited probe material because the technology
at the time Enzo Biochem filed its patent was such that it would take an
enormous amount of time for Enzo Biochem to have sequenced the DNA
probes it was claiming.78 The court laid out some very specific guidelines to
satisfy its fact based exception to Lilly: (1) the deposit had to be in a facility
which was publicly accessible; (2) the specification had to reference the
deposited material; and (3) a description must not have been available in
written form (i.e., technology would not allow for a written description of
the invention).79
III.

ANALYSIS

This note will establish that the restrictive wording used by the court
in its holding in Enzo is correct because (1) the written description
requirement is separate from the enablement requirement and needs to
remain as such; (2) Enzo is factually distinguishable from the precedent set
in Lilly; and (3) there are important societal reasons to have a more stringent
written description requirement in the area of biotechnology.
A.

Written Description v. Enablement

From the time of the Patent Act of 1793, the legislature has
recognized there is a need for a written description requirement for patents.80
Even though the function of the written description requirement has changed
over time, the statutory language requiring it has not.81 Even though there is
currently a split amongst the judges of the Federal Circuit regarding the
purpose and scope of the written description requirement,82 it has remained
through several amendments to the Patent Act, and due to its increasing
importance in patent law, it appears it is here to stay.83
Looking first to the wording of 35 U.S.C. § 112, “[t]he specification

76

Enzo, 296 F.3d at 1325.
Id. at 13 26.
78
Id.
79
Id.
80
For the historical development of the written description requirement, see supra § II (A).
81
For the historical development and the revival of the written description in biotech inventions, see
supra §§ II (A)-(B).
82
See supra n. 71 and accompanying text; Enzo, 296 F.3d at 1320.
83
For the historical development and the revival of the written description in biotech inventions, see
supra §§ II (A)-(B).
77
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shall contain a written description of the invention, and of the manner and
process of making and using it . . . ,” the statute clearly states there is a
written description requirement.84 In addition, looking at the syntax of the
statute, the placement of the comma after the word invention, and the use of
the word and after the comma would also tend to show there is a separate
written description requirement.85 Not requiring a separate written
description would make the first part of the statute superfluous, which is
against the canons of statutory construction.86 Specifically, not reading a
separate written description requirement into the statute would in essence
require removal of the comma and the word and from the statute entirely.
Interpreting the statute in light of the canons of construction necessitates a
reading of both a written description requirement and an enablement
requirement.
Looking to the history of the Patent Act itself, the legislature has
had several opportunities to remove the written description requirement
language from the statute but has chosen not to do so.87 Specifically, when
the legislature added the use of claims to the specifications, which took over
the function of the written description requirement at that time, the
legislature chose to leave in the language requiring a written description
allowing it to develop a different function over time.88 Because the
legislature chose to leave the wording within the statute, the court must give
meaning to the wording.89
Some would argue the function the written description requirement
is now serving is that of enablement.90 While in many instances, the same
information from the specification will satisfy both requirements, there are
times when an invention can be enabled but not disclosed.91 This is
especially true in the areas of biology and chemistry.92
For example, a propyl or butyl compound
may be made by a process analogous to a
disclosed methyl compound, but, in the

84

35 U.S.C.A. § 112 ¶ 1; See Enzo Biochem, Inc. v. Gen-Probe, Inc., 42 Fed. Appx. at 440 (stating that
reading the statute as to give effect to its language would require that the invention itself be described)
(Lourie, J., concurring).
85
Enzo, 42 Fed. Appx. at 440 (“note the comma between the description requirement and the enablement
provision, and the ‘and’ that follows the comma”) (Lourie, J., concurring).
86
TRW, Inc. v. Andrews, 534 U.S. 19, 31 (2001) (stating “[i]t is ‘a cardinal principle of statutory
construction’ that ‘a statute ought, upon the whole, to be so construed that, if it can be prevented, no
clause, sentence, or word shall be superfluous, void, or insignificant’”).
87
For the historical development and the revival of the written description in biotech inventions, see
supra §§ II (A)-(B).
88
Id.
89
Id.
90
Enzo, 42 Fed. Appx. at 44 5-452 (Rader, J., dissenting).
91
For a discussion of the further revival of the written descriptions in biotech inventions through Lilly,
see supra § II(B).
92
See Enzo, 42 Fed. Appx. at 443 (stating “[p]erhaps there is little difference in electrical and mechanical
inventions between describing an invention and enabling one to make and use it, but that is not true of
chemical and chemical- like inventions”) (Lourie, J., concurring).
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absence of a statement that the propyl and
butyl compounds are part of the invention,
they have not been described and they are
not entitled to a patent.93
Since it is possible to fulfill one but not the other, this would also lead to
the conclusion that they are separate requirements that overlap, but not
completely.94 As such, the two requirements are just that: two requirements,
each of which has to be fulfilled in order to meet the requirements under 35
U.S.C. § 112.
Finally, not reading a separate written description requirement into
the wording of § 112 would allow the exact problem which the Federal
Circuit in Lilly and Enzo was trying to prevent, the overreaching of claims.95
By leaving the written description wording within the statute, Congress gave
the courts an avenue by which they could help develop patent requirements
which could keep up with the fast paced environment of technological
progress. The courts have seen the hole that needed to be filled and have
now used the written description requirement to plug that hole.
B.

Enzo v. Lilly

In Enzo, some commentators see the supposed clash of the
precedent set in Lilly. Lilly required a biotech invention to disclose the
sequence of the claimed gene in order to satisfy the written description
requirement.96 Enzo allows the court to consider a deposit of biological
material along with what is disclosed in the specification to meet the written
description requirement.97 While at first glance these two cases appeared to
conflict, the factual difference in these two cases allowed the court to make
a limited factual exception to the Lilly rule.
In Lilly, the University isolated the gene in rats that produced
insulin and then tried to claim not only the gene in rats, but the gene in
humans that produced insulin, which the University never actually
isolated. 98 Basically, the University had a plan for isolating the human
insulin gene, which the University was not even sure would be successful,
and with that plan erroneously obtained a patent.99 Without ever having
isolated the gene, the University made it impossible for anyone to deduce
the sequence of the gene from the patent.100
Conversely, Enzo isolated a specific probe sequence in humans that

93

Id. at 444.
For a discussion of the further revival of the written descriptions in biotech inventions through Lilly,
see supra § II(B).
95
For a discussion on the differences between Enzo and Lilly and why biotechnology needs more
stringent requirements, see infra §§ III(B)-(C).
96
For a discussion of Lilly, see supra nn. 46-59 and accompanying text.
97
For a full discussion of Enzo, see supra §§ II(C)-(E).
98
For a discussion of Lilly, see supra nn. 46-59 and accompanying text.
99
Id.
100
Id.
94
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it used to target a specific site on the bacteria that caused gonorrhea.101 So,
at the time Enzo Biochem filed for a patent, it had not only isolated the
specific sequence that it wanted to claim, but it had performed experiments
on that specific sequence which disclosed its inherent usefulness at solving
the doctor’s false positive problem for gonorrhea tests.102 Enzo Biochem
limited its claims to that probe, disclosed the sequence to which that probe
bound, and deposited the probe material in a DNA bank.103 Even though
En zo Biochem did not specifically disclose the DNA sequence of the probe,
by making the probe available to the public, it gave others the opportunity to
obtain the sequence of the probe.
With the significant ongoing changes in biotechnology,104 the Lilly
court set a rule that would help prevent biotech inventors from overreaching
their actual invention.105 In essence, the court told the University that it
could have protection for the rat insulin gene, but not for the human insulin
gene, which it had not discovered.106 If the University wanted protection for
the human insulin gene, it needed to wait until it actually isolated the gene to
get protection. Disclosing a plan for obtaining the gene was not sufficient to
show the University had possession of the gene, which is one of the ways of
determining written description.107
In Enzo, on the other hand, the Federal Circuit allowed courts to
look at the deposited material to help determine whether the inventor was in
possession of the invention and to help prevent the overreaching of claims
seen in Lilly.108 What the court did was lay out a factually specific holding
in order to show that the preference is for the sequence to be disclosed, but
that the court will allow exceptions to this rule when the facts call for such
an exception.109 The decision in Enzo shows the Federal Circuit’s concern
for the constant changing in technology in the biotech area and demonstrates
that the court is willing to be flexible when necessary.110 Do not, however,
mistake the court’s flexibility for a shift in the law. In the Federal Circuit,
all opinions by three judge panels set precedent.111 That said, it requires an
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en banc decision to overturn precedent set by a three judge panel.112 The
court had the opportunity to hear this case en banc and overturn Lilly but
chose not to do so stating “although it was true that the written description
requirement has been applied vigorously in some recent cases, [none] . . . of
those cases were decided wrongly.”113 The refusal to hear the case en banc
and the restrictive wording in the holding shows the court is willing to be
flexible, but feels the need to keep the more stringent requirement as the
precedent in order to ensure that biotechnological inventors are not
overreaching the true breadth of their inventions.114
C.

Why Biotechnology Needs a More Stringent Written Description
Requirement

From the time of the Framers, the ability to receive a reward for an
invention has been a well accepted idea.115 This idea has developed into
modern patent law, which grants an inventor a monopoly for a certain
amount of time as a reward for disclosing his invention to the public.116 The
disclosure of an invention helps further more invention as people think of
improvements or spin-offs of the patented technology.117 In addition, the
limited monopoly allows an inventor to recoup costs of developing his
invention and gives him an avenue to raise funds through investors for
future projects on which he will work.118
Disclosure is central to the idea of patent protection. Without a
sufficient disclosure, the public gains nothing. The Patent Act requires three
forms of disclosure: (1) written description, (2) enablement, and (3) best
mode.119 While most inventions cannot be enabled without adequately
being described, this is not so for many biotechnology inventions.120 As
such, the written description requirement is very important in the
biotechnology industry because it helps prevent inventors from overreaching
the true limits of their inventions.121 Take Lilly, for instance, the University
had isolated the rat gene that produced insulin and yet they claimed all
mammalian insulin genes including those of humans.122 While it is possible
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the process they disclosed for isolating the human insulin gene was
enabling, allowing this process description to allow them to claim the
human insulin gene would reward them for an invention they had not yet
invented. It was at this point that the Federal Circuit solidified its earlier
belief that there was a need for a more specific written description
requirement for biotechnology by requiring the recitation of the sequence of
the DNA when DNA is claimed.123 By refusing to overrule Lilly in Enzo,
the Federal Circuit made it clear that the problem of overreaching in biotech
patent claims is very real; and at present, requiring the inventor to recite the
sequence is the best way to prevent it.
In addition, the court has made all aware through Enzo, that
exceptions will be made to the Lilly requirement as long as the facts show a
sufficient disclosure was made without specifying the sequence.124 It seems
as long as the inventor would have been hard pressed to identify the
sequence himself and others could derive the sequence if necessary that th e
court will consider the written description requirement satisfied.125
However, the changes in sequencing technology will soon make the need for
exceptions to Lilly unnecessary.126 As of June 2003, scientists have now
sequenced the entire human genome allowing researchers to go on websites
and compare isolated proteins with possible corresponding genes.127 This
will greatly reduce time needed to find the gene which researchers would
like to patent.128 Also, the constantly improving techniques of sequencing
has itself already dramatically improved the time necessary to determine the
sequence of the gene an inventor may want to patent.129 Looking at the
special ability of biological inventors to enable overreaching claims and
how the changes in technology are facilitating the use of the sequencing
requirement set forth in Lilly, it is easy to see why the heightened written
description requirement for biotechnology inventions is here to stay. Even
though early commentators hailed Enzo as a lessening of the written
description requirement on biotech inventions, a closer look reveals that the
court purposely used restrictive language in its holding and refused to
overrule Lilly, so the first line of defense for patent overreaching would
remain intact.
IV.

CONCLUSION

The court in Enzo has shown its willingness to carve out exceptions
to the rule in Lilly when the public has received its end of the bargain, an
adequate disclosure of the invention. In addition, the court, by carving out
an exception to Lilly instead of overruling it, has made a statement that
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biotechnology is different and because of its unique characteristics it needs
to have a more stringent requirement. Because the written description
requirement has an important role in the patent system, especially within
biotechnological inventions, the court was correct in using restrictive
wording in its holding in Enzo in order to show its flexibility but also its
resolve in making biotech inventors truly show that they deserve patent
protection for what they have claimed in their application.
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